36 research outputs found
Synthesis, in vitro activity and in vivo toxicity of the new 2,3-dinitrobutadiene derivative (1E,3E)-1,4-bis(2-naphthyl)-2,3-dinitro-1,3-butadiene
Abstract
Our interesting results on the antiproliferative (in vitro) and antitumour (in vivo) activities of (1E,3E)-1,4-bis(1-naphthyl)-2,3-dinitro-1,3-butadiene (1-Naph-DNB) have more recently induced us to design and synthesize some new 1,4-diaryl-2,3-dinitro-1,3-butadienes characterized by a common arylnitrobutadiene array but with different geometric and/or functional properties. This task was undertaken with the aim to obtain new compounds with an enhanced antiproliferative activity and, possibly, a different specificity with respect to the original (lead) compound. (1E,3E)-1,4-Bis(2-naphthyl)-2,3-dinitro-1,3-butadiene (2-Naph-DNB) is one of the molecules so obtained, a structural isomer of 1-Naph-DNB provided with a different spatial arrangement. When analyzed in vitro for its inhibition of cell proliferation 2-Naph-DNB showed a remarkable activity in the range of micromolar concentrations, with significant differences, with respect to 1-Naph-DNB, against some cell lines. Furthermore, it was able to significantly trigger apoptosis, to up-regulate p53, to block cells in the G2/M phase of the cell cycle and, finally, to slightly bind to DNA forming interstrand cross-links (ISCL). 2-Naph-DNB was then analyzed for its toxic activity in vivo in CD1 mice. This allowed the determination of toxicity parameters such as the lethal doses (LD) and the maximal tolerated dose (MTD) together with the definition of the spectrum of tissue alterations due to its administration i.v. Altogether our data suggest that the idea of modifying the geometry of the lead compound 1-Naph-DNB deserves further investigation aimed at synthesizing new molecules with similar chemical functionalities but with different spatial requirements, hopefully characterized by still enhanced activities in terms of inhibition of cell proliferation and apoptosis
Cell activation and death (apoptosis) induced by IL-2: ultrastructural evidence.
Peripheral blood cells of cancer patients with advanced renal carcinoma and treated with interleukin-2 by intravenous application were studied by electron microscopy at different intervals from the beginning of rIL-2 administration. Morphofunctional modifications of lymphocytes, circulating hystiocytes containing phagocitated bodies and polimorphonucleated cells undergoing phagocytosis were observed with a time dependent increase of altered cells. The analysis of blood cells cultured in the presence of recombinant IL-2 confirmed the in vivo results. Our data suggest that IL-2 induces apoptotic phenomena in the peripheral blood cells of treated patients
Pulmonary toxicity of instilled cadmium-doped silica nanoparticles during acute and subacute stages in rats
Potential risk associated with new
nanomaterial exposure needs to be assessed. This in vivo
study investigated pulmonary effects of engineered
cadmium-containing silica nanoparticles Cd/SiNPs (1
mg/rat), silica SiNPs (600 µg/rat) and CdCl
2 (400 µg/rat)
1, 7 and 30 days after intratracheal instillation.
Comprehensive histopathological and immunocytochemical
characterization of lung damage in terms of
apoptosis, cell proliferation, inflammation, fibrosis and
metabolism were obtained.
After exposure to all treatments, lung parenchyma
showed injury patterns characterized by collapsed
alveoli, inflammation, granuloma formation, thickened
alveolar septa and bronchiolar epithelium exfoliation.
Type II pneumocytes, containing scarcely surfactantlamellated
bodies, were also observed. Apoptotic
phenomena enhanced as following, Cd/SiNPs>CdCl
2>
SiNPs. In parallel with these findings, a significant
increase of PCNA-immunoreactive cells was detected
together with high mitotic activity. Cellular localization
and distribution of IL-6, IP-10 and TGF-Ăź1 revealed an
increased expression of these cytokines as evidence of
an enhanced cellular inflammatory response. CYP450-
immunoreactivity was also enhanced, at bronchiolar
(e.g. Clara cells) and alveolar (e.g. macrophages) level
after both Cd/SiNPs and CdCl
2. These overall effects
were observed acutely and lasted until the 30th day, with
Cd/SiNPs producing the most marked effects.
Collagen-immunolabelling changed particularly 7
and 30 days after Cd/SiNPs, when a strong stromal
fibrogenic reaction occurred.
The present findings suggest that Cd/SiNPs produce
significantly greater pulmonary alterations than either
SiNPs or CdCl2 under the present experimental
conditions
Mechanisms of changes to the liver pigmentary component during the annual cycle (activity and hibernation) of Rana esculentaL.
The present study was performed to elucidate the mechanisms responsible for the changes of melanin content/distribution we had previously discovered in the liver parenchyma of Rana esculenta during natural hibernation. Melanomacrophagic component response was analysed using morphocytochemical methods. The results demonstrated that during the prehibernation period (October–November) the melanomacrophages reach the highest proliferative activity (BrdU, PCNA labelling) which is accompanied by an evident melanosynthesis (dopa-oxidase activity). In contrast, after hibernation, the decrease of liver pigmentation was the consequence of a partial cell loss by apoptotic mechanisms (TUNEL labelling, pyknosis-karyorhexis) accompanied by a decrease of melanosome content by autophagy and low melanosynthetic activity. On the basis of these findings, there is evidence that liver melanomacrophages represent a metabolically (melanin synthesis/degradation) and cytokinetically (proliferation/death) active cell population during the annual cycle of the frog. The results are also discussed in relation to the functional synergism between hepatocytes and pigment cells in the adaptation to environmental changes
Cyclodextrin polymers as nanocarriers for sorafenib
Polymeric nanoparticles based on cyclodextrins are currently undergoing clinical trials as new promising nanotherapeutics. In light of this interest, we investigated cyclodextrin cross-linked polymers with different lengths as carriers for the poorly water-soluble drug sorafenib. Both polymers significantly enhanced sorafenib solubility, with shorter polymers showing the most effective solubilizing effect. Inclusion complexes between sorafenib and the investigated polymers exhibited an antiproliferative effect in tumor cells similar to that of free sorafenib. Polymer/Sorafenib complexes also showed lower in vivo tissue toxicity than with free sorafenib in all organs. Our results suggest that the inclusion of sorafenib in polymers represents a successful strategy for a new formulation of this drug